Search

Your search keyword '"A. de Groot"' showing total 848 results

Search Constraints

Start Over You searched for: Author "A. de Groot" Remove constraint Author: "A. de Groot" Journal blood Remove constraint Journal: blood
848 results on '"A. de Groot"'

Search Results

4. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

5. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

6. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

7. Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments

8. Molecular Diagnostics for TP53 Is Recommended in B-Cell Lymphomas

10. Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

11. Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen

13. Delayed normalisation of ADAMTS13 activity in acute Thrombotic Thrombocytopenic Purpura in the caplacizumab era

14. Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments

15. Molecular Diagnostics for TP53 Is Recommended in B-Cell Lymphomas

17. Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

19. Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen

20. Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders

23. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL

25. Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders

28. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

29. Long-term outcomes of Sleeping Beauty–generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

40. A Validated Risk Prediction Model for Bone Fragility in Children with Acute Lymphoblastic Leukemia

41. Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG

48. Implementation of Continuous Pegasparaginase Dosing without an Asparaginase-Free Interval Reduces Hypersensitivity in Children with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of the DCOG ALL11 Pegasparaginase Randomization

49. Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Catalog

Books, media, physical & digital resources